GSK716155

DRUG2 trials

Sponsors

GlaxoSmithKline

Conditions

Diabetes Mellitus, Type 2Heart Failure, Congestive

Phase 1

Scintigraphy Study to Assess Gastric Emptying in Healthy Subjects Given GSK716155 or Placebo.

CompletedNCT00537719

GlaxoSmithKlineDiabetes Mellitus, Type 2

Start: 2007-12-07End: 2008-04-04Updated: 2017-08-17

Phase 2

A Multi-center, Placebo-controlled Study to Evaluate the Safety of GSK716155 and Its Effects on Myocardial Metabolism, Myocardial Function, and Exercise Capacity in Patients With NYHA Class II/III Congestive Heart Failure

CompletedNCT01357850

GlaxoSmithKlineHeart Failure, Congestive

Start: 2010-09-15End: 2012-09-18Updated: 2017-08-17

Related Papers

Effects of the Novel Long-Acting GLP-1 Agonist, Albiglutide, on Cardiac Function, Cardiac Metabolism, and Exercise Capacity in Patients With Chronic Heart Failure and Reduced Ejection Fraction.

2016-03-30101 citations

Clinical pharmacology of albiglutide, a GLP-1 receptor agonist.

2014-11-0128 citations